Impulse Control Disorders Arising in 3 Patients Treated With Rotigotine

  title={Impulse Control Disorders Arising in 3 Patients Treated With Rotigotine},
  author={Thomas S. Wingo and Marian Leslie Evatt and Burton L. Scott and Alan Freeman and Mark Stacy},
  journal={Clinical Neuropharmacology},
Objective:We report 3 cases of impulse control disorders (ICDs) that developed in patients with Parkinson disease treated with the novel dopamine agonist, rotigotine. Methods:Three patients were identified retrospectively who developed symptoms of an ICD while taking rotigotine. The ICD symptoms developed at 4, 5, and 8 years after diagnosis of Parkinson disease in these patients and while they were taking rotigotine and levodopa. Other drugs included entacapone, amantadine, and selegiline. The… 
Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome.
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study
Since pramipexole, ropinirole and rotigotine are non-ergolinic DAs with very similar pharmacodynamic profiles, it is likely that other factors including route of administration (transdermal vs oral) explain the difference in risk of ICD development.
Impulse Control Disorders Associated With Dopaminergic Medication in Patients With Pituitary Adenomas
This study demonstrates the importance of systematic screening for ICDs in patients taking dopaminergic medication regardless of their primary condition, and indicates the need for systematic screening in patients with pituitary adenomas who take dopamine agonists.
Safety and Tolerability of Transdermal Rotigotine in a Clinical Practice Cohort for 2 Years
Rotigotine is safe and well tolerated when used to treat PD in routine clinical practice, and necessitated the discontinuation of rotigotine for application site reactions in fourteen patients.
Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management
This review aims to summarise the current literature on ICDs, their phenomenology, epidemiology, clinical features, pathophysiology and management, and to suggest an optimal treatment for patients with PD.
Rotigotine transdermal patch for the treatment of Parkinson’s Disease
The rotigotine transdermal patch offers a safe and efficacious alternative for the treatment of PD and further studies should focus on the possibility that continuous dopamine stimulation by means of the transDermal patch has any influence on levodopa‐related motor complications.
A systematic review of impulse control disorders in Parkinson's disease.
A systematic overview of literature published between 2000 and January 2013 reporting impulse control disorders in Parkinson's disease is presented and prevalence rates and the functional neuroanatomy, the impact of dopamine-serotonin interactions, and the cognitive symptomatology associated with impulse control Disorders in Parkinson’s disease are discussed.
Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome
The constant transdermal delivery of rotigotine over 24 h is hypothesized to approximate continuous agonist–receptor stimulation, which conceptually more closely mimics physiologic striatal dopamine receptor function.


Rotigotine: in Parkinson's disease.
Rotigotine was generally well tolerated in clinical trials as both monotherapy and when administered with levodopa; adverse events were generally mild or moderate in severity.
Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy
Patients treated with levodopa for 4 to 8 years were significantly more impaired with parkinsonism than patients treated for 0 to 3 years, even when patients were matched for total duration of disease.
Behavioral Complications of Drug Treatment of Parkinson's Disease
  • J. Cummings
  • Psychology, Medicine
    Journal of the American Geriatrics Society
  • 1991
Dopaminergic agents share the property of stimulation of D2 dopamine receptors, and this action may play an essential role in mediating their neuropsychiatric effects, and lithium may help control drug‐induced mania.
Parkinson's disease: drug-induced psychiatric states.
Although drug-induced psychoses are the most important of the drug- induced psychiatric states, mania, anxiety, and hypersexuality may also occur, and depression is also common in PD, but it is unlikely to occur as a side effect of antiparkinsonian medications.
Pathological gambling caused by drugs used to treat Parkinson disease.
Dopamine agonist therapy was associated with potentially reversible pathological gambling, and pramipexole was the medication predominantly implicated.
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
Transdermal rotigotine, in a continuous-dosing transdermal-patch formulation, when titrated to a dosage of 6 mg/24 h, was effective for the treatment of early-stage Parkinson disease in this trial.
Association of dopamine agonist use with impulse control disorders in Parkinson disease.
Patients with PD treated with a dopamine agonist should be made aware of the risk of developing an ICD and monitored clinically, and the dopamine agonists-associated risk for ICDs in other populations should be assessed.
History of levodopa and dopamine agonists in Parkinson's disease treatment
Dopamine agonists began to find a place in routine treatment of PD after the discovery of bromocriptine's benefits in PD in 1974, and new approaches have been tried, such as dopamine agonist monotherapy and early therapy in combination with levodopa.
Prevalence of pathological gambling in patients with Parkinson's disease
The results emphasize that PG in patients with idiopathic PD on dopamine replacement therapy is an emergent comorbidity, but probably at present the condition is not properly diagnosed because it is mostly unknown.